Press Releases 

Helomics Launches CellFx, A Key Research Component

Helomics® Launches CellFx™, A Key Research Component of their Precision Cellular Analytical Platform (PCAP™) Further Expanding their Comprehensive Tumor Profiling Offering to Patients, Physicians and Life Science Industry The CellFx™ platform allows for a personalized full tumor biology characterization of a patient’s tumor PITTSBURGH - February 8, 2016 - Helomics® Corporation (Helomics®), a privately-held, personalized healthcare company that provides comprehensive tumor profiling utilizing proprietary live cell and fixed cell products and services announced today that it will be launching, in March 2016, CellFx™, a new research component of the company’s Precision Cellular Analytical Plat

Helomics Launches DEFENDER

Helomics® Launches the DEFENDER™Live Cell Liquid Biopsy System The DEFENDER™ Live Cell Liquid Biopsy System is the world’s only live cell liquid biopsy to detect all components of a patient’s shedding tumor Novel Proprietary Component of Precision Cellular Analytical Platform (PCAP™), Further Expanding its Comprehensive Tumor Profiling Offering to Patients, Physicians, and Life Science Industry PITTSBURGH & LONDON - February 9, 2016 - Helomics® Corporation, a privately-held, personalized healthcare company that provides comprehensive tumor profiling utilizing proprietary live cell and fixed cell products and services, announced today the launch of the DEFENDER™ Live Cell Liquid Biopsy Syste

Archive
 Follow Us
  • LinkedIn Social Icon
  • Facebook Basic Square
  • Twitter Basic Square

© 2020 Helomics Corp. All rights reserved.

  • White Twitter Icon
  • Facebook - White Circle
  • White LinkedIn Icon